Chiesi Farmaceutici S.p.a.

This study continues testing an enzyme replacement therapy called pegunigalsidase alfa in adults with Fabry disease who finished a previous trial. Researchers want to understand the long-term safety and effectiveness of receiving this medication through an IV every four weeks. Th…